neuropsychiatric symptoms Tagged Articles

New warnings added to Chantix label include cardiovascular events, psychiatric symptoms

Posted: March 20, 2013 Pharmaceutical

The safety label for the smoking cessation drug Chantix (varenicline) has been updated to include new warnings about cardiovascular risks. The warning is based on a large, combined analysis of clinical trials that showed more serious cardiovascular events occurred in

New warnings for off-label smoking addiction drug Aplenzin

Posted: May 23, 2011 Product Liability

The antidepressant Aplenzin (bupropion hydrobromide) extended-release tablets has a new black box warning against the use of the drug to help people quit smoking. The drug is approved by the Food and Drug Administration (FDA) only for the treatment of

Support group says Chantix ads conceal important information

Posted: January 11, 2010 Pharmaceutical

WhyQuit, an organization that advocates quitting smoking using the cold turkey method, recently published an article that takes Pfizer to task over its latest Chantix ads. The group claims that the pharmaceutical company’s new television commercials hide information from the

Family of musician killed in Chantix rage sues Pfizer

Posted: September 8, 2009 Pharmaceutical

The family of musician Carter Albrecht has filed a lawsuit in a Dallas federal court against Chantix manufacturer Pfizer Inc. Ken and Judy Albrecht allege that the drug manufacturer is responsible for the musician’s death in 2007 because it marketed

FDA approves stronger, expanded warnings on Chantix labeling

Posted: August 27, 2009 Pharmaceutical

The Food and Drug Administration has approved the new labeling for Chantix packaging. In July, we reported that the agency said it would require stronger warnings on all Chantix labeling, as well as packaging for other smoking cessation drugs Wellbutrin and